Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anas Abdel Azim

Vascular Surgery Greenwood, SC Medical Doctor

NPI 1104131143 CMS profile 1393318

160 Academy Ave, Greenwood, SC 29646

Open in the dashboard

General payments

$7,512

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anas Abdel Azim of Greenwood, SC is reported in the CMS Open Payments database as having received $7,512 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $785 44
2024 General $558 37
2023 General $480 13
2022 General $3,692 57
2021 General $286 12
2020 General $712 11
2019 General $999 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anas Abdel Azim
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Anas Abdel Azim were reported at $785. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Anas Abdel Azim Vascular Surgery median Middle half National median
2019 $999 $796 $226–$2,363 $163
2020 $712 $348 $118–$1,110 $114
2021 $286 $471 $158–$1,421 $132
2022 $3,692 $725 $222–$2,183 $149
2023 $480 $836 $257–$2,440 $160
2024 $558 $909 $252–$2,619 $164
2025 $785 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,641 20 payments
  2. Medtronic Vascular, Inc. $1,583 22 payments
  3. Cardiovascular Systems Inc. $1,121 3 payments
  4. Endologix, Inc. $894 10 payments
  5. Inari Medical, Inc. $540 12 payments
  6. Abbott Laboratories $524 72 payments
  7. Penumbra, Inc. $233 3 payments
  8. Boston Scientific Corporation $108 6 payments
  9. Philips Electronics North America Corporation $98 2 payments
  10. Stryker Corporation $89 4 payments
  11. Other $683 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,928 177 payments
  2. Travel and Lodging $2,546 11 payments
  3. Education $38 1 payment
Products named General payments · program years 2019–2025
  1. Valiant Captivia $1,469 13 payments
  2. Diamondback Peripheral $1,121 3 payments
  3. AFX2 Bifurcated Endograft System $705 8 payments
  4. Endurant $669 6 payments
  5. ClosureFast $624 7 payments
  6. Ovation iX Iliac Stent Graft $607 6 payments
  7. CT THROMBECTOMY SYSTEM KIT $590 15 payments
  8. FLOWTRIEVER CATHETER, S $590 15 payments
  9. ESPRIT $181 24 payments
  10. Penumbra System $151 2 payments
  11. Other $2,361 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

691

Median for Vascular Surgery: 122

Drug cost

$61,190

Median for Vascular Surgery: $14,135

Branded share of claims

43.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 62 $41,437
Xarelto Rivaroxaban Brand 11 $12,360
Cilostazol Generic 150 $3,057
Clopidogrel Clopidogrel Bisulfate Brand 226 $2,217
Rosuvastatin Calcium Generic 63 $927
Atorvastatin Calcium Generic 140 $915
Ezetimibe Generic 20 $245
Tramadol Hcl Generic 19 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$163,704

Medicare's payments for the services billed

Medicare patients

1,306

Average age 76

Services billed

2,757

595 women, 711 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 40%
Ischemic heart disease 39%
Chronic kidney disease 39%
Heart failure 29%
Atrial fibrillation 24%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record